TEL AVIV, Israel, March 16, 2017 /PRNewswire/ -- Galmed
Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a
clinical-stage biopharmaceutical company focused on the development
of a once-daily, oral therapy for the treatment of nonalcoholic
steatohepatitis, or NASH, and other liver diseases, announced today
that it will host a conference call and webcast on Thursday, March 23rd, 2017, to provide
an update on its clinical programs and its new insights into the
mechanism of actions of Aramchol as well as to discuss financial
results for the period ended December 31,
2016.
Conference Call &
Webcast:
Thursday, March
23rd, 2017, 8:30 am Eastern
Time / 5:30 am Pacific
Time
Participant Dial-In Numbers:
Toll-Free: +1-888-663-2242
Toll/International:
+1-913-312-0380
Conference
ID: 3745268
Webcast: http://galmedpharma.investorroom.com/events
Replay, available until April 6,
2017
Replay Dial-In Numbers:
Toll-Free: +1-844-512-2921
Toll/International:
+1-412-317-6671
Passcode: 3745268
About Aramchol™ and Non-alcoholic
Steatohepatitis (NASH)
Aramchol™ (arachidyl
amido cholanoic acid) is a novel fatty acid bile acid conjugate,
inducing beneficial modulation of intra-hepatic lipid metabolism.
Aramchol™'s ability to modulate hepatic lipid
metabolism was discovered and validated in animal models,
demonstrating down regulation of the three key pathologies of NASH;
steatosis, inflammation and fibrosis. The effect of
Aramchol™ on fibrosis is mediated by down
regulation of steatosis and directly on human collagen producing
cells. Aramchol™ has been granted by the FDA Fast
Track designation status for the treatment of NASH.
NASH is an emerging world crisis impacting 3% to 5% of the U.S.
population and 2% to 4% globally. It is the fastest growing cause
of liver cancer and liver transplant in the U.S. due to the rise in
obesity. NASH is the progressive form of non alcholic fatty liver
disease that can lead to cardiovascular disease, cirrhosis and
liver-related mortality.
About Galmed Pharmaceuticals Ltd.:
Galmed is a
clinical-stage biopharmaceutical company focused on the development
of Aramchol™, a first in class, novel, once-daily,
oral therapy for the treatment of NASH for variable populations, as
well as other liver associated disorders. Galmed is currently
conducting the ARREST Study, a multicenter, randomized, double
blind, placebo-controlled Phase IIb clinical study designed to
evaluate the efficacy and safety of Aramchol™ in
subjects with NASH, who are overweight or obese, and who are
pre-diabetic or type-II-diabetic. Galmed also sponsors the ARRIVE
Study, a proof-of-concept Phase IIa clinical trial designed to
evaluate the safety and efficacy of Aramachol in up to 50 patients
with HIV-associated NAFLD and lipodystrophy. The ARRIVE Study is an
investigator-initiated trial, conducted at the University of California San Diego by Professor
Rohit Loomba. More information about
the ARREST Study and the ARRIVE Study may be found on
ClinicalTrials.gov identifiers: NCT02279524 and NCT02684591,
respectively.
Forward-Looking Statements:
This press release may
include forward-looking statements. Forward-looking statements may
include, but are not limited to, statements relating to Galmed's
objectives, plans and strategies, as well as statements, other than
historical facts, that address activities, events or developments
that Galmed intends, expects, projects, believes or anticipates
will or may occur in the future. These statements are often
characterized by terminology such as "believes," "hopes," "may,"
"anticipates," "should," "intends," "plans," "will," "expects,"
"estimates," "projects," "positioned," "strategy" and similar
expressions and are based on assumptions and assessments made in
light of management's experience and perception of historical
trends, current conditions, expected future developments and other
factors believed to be appropriate. Forward-looking statements are
not guarantees of future performance and are subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied in such statements. Applicable
risks and uncertainties include risks and uncertainties associated
with the initiation, timing, progress and results of the Company's
research, preclinical studies and clinical trials as well as risks
and uncertainties identified under the heading "Risk Factors"
included in Galmed's most recent Annual Report on Form 20-F filed
with the Securities and Exchange Commission, or the SEC, on
March 22, 2016, and in other filings
that Galmed has made and may make with the SEC in the future. The
forward-looking statements contained in this press release are made
as of the date of this press release and reflect Galmed's current
views with respect to future events, and Galmed does not undertake
and specifically disclaims any obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-fourth-quarter-2016-conference-call-and-webcast-scheduled-for-thursday-march-23rd-2017-300423234.html
SOURCE Galmed Pharmaceuticals Ltd.